Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$20.45 +1.9%	$17.97	$13.53 ▼ $35.25	$2.02B	2.07	1.57 million shs	2.00 million shs
BPMC Blueprint Medicines	$129.46 +0.1%	$119.38	$73.04 ▼ $129.65	$8.35B	0.89	1.53 million shs	2.98 million shs
DNLI Denali Therapeutics	$14.53 -2.3%	$14.24	$10.57 ▼ $33.33	$2.16B	1.33	1.15 million shs	1.03 million shs
ROIV Roivant Sciences	$11.65 +1.0%	$11.14	$8.73 ▼ $13.06	$7.84B	1.15	5.74 million shs	4.46 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.89%	-7.17%	+22.68%	+20.29%	-24.06%
BPMC Blueprint Medicines	+0.14%	+0.10%	+0.96%	+52.98%	+13.20%
DNLI Denali Therapeutics	-2.29%	-5.34%	+3.71%	+14.05%	-36.85%
ROIV Roivant Sciences	+0.95%	+0.69%	+4.86%	+14.78%	+3.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.2432 of 5 stars	3.5	0.0	0.0	3.1	2.5	0.6
BPMC Blueprint Medicines	1.1282 of 5 stars	2.1	2.0	0.0	2.5	0.8	0.6
DNLI Denali Therapeutics	4.681 of 5 stars	4.5	1.0	4.7	3.9	3.3	0.0
ROIV Roivant Sciences	2.6493 of 5 stars	3.6	3.0	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	138.39% Upside
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.93% Downside
DNLI Denali Therapeutics	3.06	Buy	$33.71	132.03% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	41.63% Upside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, BPMC, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	32.37	N/A	N/A	$8.86 per share	2.31
BPMC Blueprint Medicines	$508.82M	16.43	N/A	N/A	$4.70 per share	27.54
DNLI Denali Therapeutics	$330.53M	6.39	N/A	N/A	$8.53 per share	1.70
ROIV Roivant Sciences	$29.05M	272.63	N/A	N/A	$7.45 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest DNLI, BEAM, BPMC, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	ROIV Roivant Sciences	-$0.23	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
BPMC Blueprint Medicines	1.01	2.80	2.75
DNLI Denali Therapeutics	N/A	9.56	9.56
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
BPMC Blueprint Medicines	N/A
DNLI Denali Therapeutics	92.92%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
BPMC Blueprint Medicines	4.21%
DNLI Denali Therapeutics	12.50%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

DNLI, BEAM, BPMC, and ROIV Headlines

Recent News About These Companies

CenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 16 at 10:50 AM | marketbeat.com

Bank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 15 at 3:30 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Rating Upgraded by The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Roivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?

July 9, 2025 | marketbeat.com

DAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 9, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement System

July 9, 2025 | marketbeat.com

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months

June 28, 2025 | msn.com

Roivant Sciences’ president Venker sells $1.15 million in shares

June 26, 2025 | investing.com

Investors Buy Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)

June 26, 2025 | marketbeat.com

Penn Davis Mcfarland Inc. Has $17.23 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 25, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in Stock

June 25, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

June 24, 2025 | marketbeat.com

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24, 2025 | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24, 2025 | insidertrades.com

Roivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millions

June 23, 2025 | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in Stock

June 23, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of Stock

June 23, 2025 | marketbeat.com

Assenagon Asset Management S.A. Takes $570,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 20, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Up 5.4% - What's Next?

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, BPMC, and ROIV Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$20.45 +0.38 (+1.89%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$20.50 +0.05 (+0.27%)

As of 07/17/2025 07:55 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Blueprint Medicines NASDAQ:BPMC

$129.46 +0.18 (+0.14%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$129.48 +0.02 (+0.02%)

As of 07/17/2025 05:56 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$14.53 -0.34 (-2.29%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$14.40 -0.13 (-0.89%)

As of 07/17/2025 07:45 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Roivant Sciences NASDAQ:ROIV

$11.65 +0.11 (+0.95%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$11.54 -0.12 (-0.99%)

As of 07/17/2025 07:37 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time